Shares of Regeneron Pharmaceuticals, Inc. REGN have gained 13.5% in the year so far against the industry’s decline of 2.8%.

The stock's rise snapped a five-day losing streak.

For the biopharma industry to match the pace of genomic innovations and speed new therapies to market, it will need to ...

Symptoms and activity improved in patients with chronic obstructive pulmonary disease and type 2 inflammation.

Ebglyss' approval highlights the opportunity that exists in the AD space, and may have potential advantages in efficacy and ...

Intellia Therapeutics, Inc. NTLA announced that it has initiated the pivotal phase III HAELO study evaluating NTLA-2002 for ...

Regeneron also said it was discontinuing a phase 3 study of REGN1908-1909, a multi-antibody therapy to Fel d 1 being studied as a treatment for cat allergy, due to futility. Image Phil Taylor ...

Regeneron has formed a corporate venture capital unit with $100 million a year to invest over the next five years in “biopharmaceutical, healthcare, and health technology” start-ups.

Ana Baramidze, MD, PhD, discussed 5-year follow-up results from the EMPOWER-Lung study evaluating cemiplimab vs chemotherapy ...

Democratic Vice President Kamala Harris led Republican Donald Trump by a marginal three percentage points - 46% to 43% - as the two remain locked in a close race to win the Nov. 5 U.S ...

PhD candidate Momodou Taal is facing expulsion and the termination of his visa for his role in the Cornell University student encampment for Gaza. The Vice Presidential debate was, for many, a ...

'People have supported us more than we expected': NC vice president Omar Abdullah "We should wait for the final results to come. Only after that we can say something. As of now, I am really happy ...